BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Repeat Offender: Baxter BioScience Corporation (BAX), the FDA and Too Much Mold to Count


6/12/2013 8:00:33 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

As the FDA continues its push to crack down on manufacturing violations, warning letters have become standard fare. But every so often, a missive stands out from the crowd thanks to the sort of violations that the agency encounters. The latest example is Baxter Healthcare, which has become a repeat offender with serious problems at a few different plants. For instance, a Baxter plant in North Carolina had various environmental issues. Specifically, there was a failure to sanitize and sterilize some equipment and the agency found that various filters and screen used in a product fill line had contained “varying amounts of discolored areas, chipping paint, multi-colored coalescing droplets and clumps of dark material that FDA testing later revealed was mold.” Although Baxter halted shipments of products made on that line after the November 2012 agency inspection, the FDA noted the drugmaker did not determine how long the problems existed and failed to identify how the mold was allowed to “proliferate to a level of TNTC (Too Numerous Too Count) in several environmental samples directly over your fill line.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->